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Polyamines are small polycationic molecules with flexible carbon chains that are 
found in all eukaryotic cells. Polyamines are involved in the regulation of many host 
processes and have been shown to be implicated in viral replication. Depletion of 
polyamine pools in cells with FDA approved drugs restricts replication of diverse RNA 
viruses. Viruses can exploit host polyamines to facilitate packaging, transcription, 
translation, and protease activity but other mechanisms remain largely unknown.  
Picornaviruses, including Coxsackievirus B3 (CVB3), are sensitive to depletion of 
polyamines and remain a significant public health threat. We employed CVB3 as a 
model system to investigate a potential pro-viral role for polyamines using a forward 
screen. Passaging CVB3 in polyamine depleted cells generated a mutation in capsid 
protein VP3 at residue 234, which is involved in receptor binding. We show this 
mutation confers resistance to polyamine depletion. Through attachment assays, we 
demonstrate that polyamines facilitate CVB3 attachment to susceptible cells, and that 
the capsid mutant rescues this inhibition in polyamine depleted cells. More divergent 
viruses also exhibited reduced attachment to polyamine depleted cells, suggesting that 
polyamines may facilitate attachment of diverse RNA viruses. Virus-receptor 
interactions are involved in the pathogenesis, transmission, and host range of viruses; 
thus understanding this process is crucial to combating virus infection. Further, these 
studies inform additional mechanisms of action for polyamine-depleting pharmaceuticals 







Enteroviruses and CVB3 
Enteroviruses are non-enveloped positive-sense RNA viruses that are members 
of the Picornaviridae family. Enteroviruses are a significant threat to public health and 
lead to at least 10-15 million infections per year in the US alone (1). Coxsackievirus B3 
(CVB3) was the fifth most commonly reported enterovirus in the US between 2014-2016 
causing 4% of reported enterovirus infections (2).  A study in Yantai, China, found that 
CVB3 infections were widely distributed, with a seroprevalence of 52.3% (3).  Further, 
CVB3 is a significant contributor to the development of viral myocarditis and dilated 
cardiomyopathy (4, 5), as well as other severe conditions such as aseptic meningitis (6). 
There are currently no standard antivirals or vaccines that can be used to prevent or 
treat infections. Thus, discovering novel aspects of CVB3 replication could uncover 
potential therapeutic targets that may prevent many of the pathologies associated with 
this and related viruses. 
CVB3 Structure
Picornaviruses, including CVB3, are non-enveloped with an icosahedral capsid. 
The capsid itself is composed of 60 protomers with each protomer composed of one 
copy of each of the four viral structural proteins, VP1-4  (7, 8). VP1-3 are located on the 





icosahedral symmetry of the capsid generates two-fold, three-fold, and five-fold axes of 
symmetry. Surrounding the five-fold axis of symmetry is a deep depression in the capsid 
termed the “canyon” (8). At the bottom of the canyon is a hydrophobic pocket filled with 
a “pocket factor” thought to be a fatty acid (8, 9). The release of the pocket factor is 
important for conformational changes in the capsid for release of the viral RNA (10–12). 
A receptor binding site for CVB3 is located at the bottom of the canyon and binding to 
this site is thought to be involved in expelling the pocket factor (11–13).  
 
 
Figure 1. Structure of Enteroviruses. Illustration of the capsid structure of an 
enterovirus. The external surface of the capsid is composed of repeating units of 
proteins VP1-3. The icosahedral capsid has a five-fold, three-fold, and two-fold axis of 
symmetry as indicated. Surrounding the five-fold axis of symmetry is a depression 
termed the “canyon”. In the canyon is the “pocket factor” as well as a receptor binding 
site. Adapted from Combelas et al., 2017 (14). 
 
Viral Attachment 
The entry of a virus into a host cell is the crucial first step in viral replication. Viral 
entry begins with attachment to the surface of a cell, which is often mediated by 





often proteoglycans such as heparan sulfate (15). Heparan sulfates are a very 
promiscuous attachment factor that are utilized by many viruses. CVB3 (16, 17), Zika 
(18), multiple Enteroviruses including some rhinoviruses (19–24), Rift Valley Fever virus 
(25), and many other viruses bind heparan sulfate (15). Viruses also bind to specific 
cellular receptors that lead to the ultimate uptake of the virus through fusion or 
endocytosis, usually mediated by conformational changes to the capsid and by 
recruitment of cellular machinery. 
 Understanding mechanisms of virus-receptor interactions is critically important 
not only from a basic virology perspective but also because virus-receptor binding has 
clinical implications, as virus-receptor binding often restricts tissue tropism, affects 
pathogenesis, contributes to transmission mechanisms, and restricts species specificity 
(26–34). 
CVB3 Attachment to Cells 
CVB3 uses the coxsackie and adenovirus receptor (CAR), the decay-
accelerating factor (DAF), and possibly heparan sulfate for attachment and entry into 
cells (16, 17, 35, 36). Attachment to these receptors are critical for downstream viral 
entry events. 
 CAR is a transmembrane protein often found in tight junctions and is expressed 
on many types of epithelial cells (37). CAR is found in a variety of tissues including the 
heart, brain, lungs, intestines, liver, and kidneys (38–42). It is primarily an adhesion 
protein in the Junction Adhesion Molecule (JAM) family in the immunoglobulin 
superfamily and plays major roles in cell-cell adhesion and embryonic development (38, 





across epithelial cell junctions (45). CAR is a receptor for group B coxsackieviruses as 
well as multiple adenoviruses (36). The binding site for CAR lies at the bottom of the 
“canyon” around the five-fold axis of symmetry (13). CAR binding is crucial to CVB3 
entry as it leads to a conformation change in the capsid necessary for uncoating and 
release of the viral RNA (11–13).  
DAF is a glycosylphosphatidylinositol (GPI)-anchored protein that primarily 
functions as a complement inhibitor by inhibiting the C3 convertase (46, 47) and is 
expressed on virtually all serum exposed cells (48). DAF is utilized as a receptor by a 
large number of enteroviruses such as coxsackievirus A21, B1, B3, B5, multiple 
echoviruses, and enterovirus 70 (35, 49–53) . Attempts to map the DAF binding sites on 
these viruses have revealed differences in binding sites on both the virus and DAF itself 
suggesting that DAF binding may have evolved independently for multiple viruses (52). 
The binding of CVB3 to DAF without CAR interactions is not sufficient for infection (35). 
CVB3 bound to DAF does not trigger the necessary conformation change for further 
capsid uncoating events and structural studies have revealed that DAF-virus 
interactions occur on the virus surface, not in the canyon as with CAR (35, 54). There 
are multiple strains of CVB3, and certain strains, including clinical isolates, that bind 
DAF but others do not (35, 55, 56). Rhabdomyosarcoma (RD) cells express DAF but 
low transient levels of CAR (57). Passage of the non-DAF binding variant Nancy on RD 
cells results in the emergence of a DAF binding variant, CVB3-RD (58, 59). 
Characterization of the amino acid differences between DAF-binding and non-DAF-
binding variants reveals two major residues that mediate this difference (56). Mutation 





ability of Nancy to bind DAF (56). Another mutation, asparagine to aspartate (N to D) at 
residue 138 in VP2, was also shown to be required for DAF binding (56). Both of these 
residues, 138 in VP2 and 234 in VP3, have been shown to be in direct contact with 
bound DAF (54, 56). 
In addition to binding DAF and CAR, CVB3 also appears to utilize the 
proteoglycan heparan sulfate as an entry receptor and/or attachment factor. Treatment 
of cells with a heparan sulfate degrading enzyme reduced CVB3 attachment to cells 
(16). Additionally, a variant of CVB3, CVB3-PD, can utilize the proteoglycan heparan 
sulfate as an entry receptor in the absence of CAR or DAF binding (17). 
CVB3 Entry into Cells 
CVB3 entry into a host cell after attachment is complex and occurs through 
multiple mechanisms. One of the most characterized mechanisms involves the entry of 
CVB3 into polarized intestinal epithelial cells. This process involves the binding of CVB3 
to DAF expressed on the apical surface of cells (60). When CVB3 binds to DAF, DAF 
molecules cluster and activate the nonreceptor tyrosine kinases Fyn and Abl (60). Abl 
activation leads to RAC dependent cytoskeletal rearrangements that allow CVB3 to 
migrate into tight junctions where it can bind to CAR (60). The binding site for CAR on 
CVB3 lies at the bottom of the canyon (13). At the bottom of the canyon is the pocket 
factor (a fatty acid) (8, 9). When CAR binds into the canyon the pocket factor is expelled 
and the capsid undergoes a conformational change that leads to the release of VP4 
from the virus and primes the virus for release of its RNA (10–12). The conformational 
change in the capsid after CAR binding generates what are known as altered particles 





cell via caveolin dependent endocytosis facilitated by Fyn dependent phosphorylation of 
caveolin-1 (60). Enteroviruses like CVB3 are thought to eject their RNA into the cytosol 
through a pore formed in the host membrane (61–63). This pore is generated from 
exposed hydrophobic residues on VP1 and from VP4 that was released during A 
particle formation (61–63). This process is summarized in Fig. 2. 
 
Figure 2. Entry of CVB3 into Polarized Intestinal Epithelial Cells. A simplified 
illustration of the entry of CVB3 into polarized intestinal epithelial cells. CVB3 binds DAF 
which causes DAF to cluster and trigger a signaling cascade that activates the tyrosine 
kinases Fyn and Abl. Activation of Fyn and Abl lead to tight junction permeabilization 
allowing CVB3 to bind CAR as well as phosphorylation of caveolin-1. CVB3 is 
endocytosed via caveolin-1 mediated endocytosis (60). 
 
CVB3 enters nonpolarized cells differently, as CVB3 does not require DAF when 
CAR is accessible and not sequestered in tight junctions (64). DAF-binding and non-
DAF-binding have been suggested they enter non-polarized cells via the same 
mechanism (64). While DAF-binding was not necessary for entry into nonpolarized 






Polyamines are small, polycationic molecules with flexible carbon chains that are 
found in all mammalian cells (65). They are involved in many cellular processes 
including protein synthesis, regulation of gene expression, regulation of ion channels, 
cell cycling, and many others (66–73). Knockout of key polyamine synthesis genes is 
embryonically lethal in mice (66, 74). Spermidine is a substrate for the hypusination of 
the eukaryotic initiation factor 5A (eIF5A), a translation factor, and this is necessary for 
its function (75–78) . The amino acid hypusine is generated from the activity of two 
enzymes, deoxyhypusine synthase and deoxyhypusine hydroxylase and is only found in 
one protein, eIF5A (75–77). Polyamines also have functions in the structure of nucleic 
acids. They facilitate the transition of B form DNA to Z form DNA, can bend DNA 
structure, and are involved in stabilizing the structure of tRNA (79–84). Further, 80% of 
polyamines in the cell are found associated with RNA (68).  
 
Figure 3. The Mammalian Polyamines. The biogenic polyamines putrescine, 






There are three biogenic polyamines in mammals, putrescine, spermidine, and 
spermine. The structure of these polyamines is shown in Fig. 3. Polyamines are 
synthesized beginning with the decarboxylation of an ornithine molecule by ornithine 
decarboxylase (ODC) generating putrescine (85). Putrescine can then be converted into 
spermidine and subsequently converted to spermine by the addition of aminopropyl 
groups by the aminopropyltransferases, spermidine synthase and spermine synthase by 
utilizing decarboxylated S-adenosylmethionine (dcAdoMet) as an aminopropyl donor 
(86). S-adenosylmethionine decarboxylase (AdoMetDC) produces dcAdoMet from S-
adenosylmethionine (AdoMet) and this process is important as it diverts cellular pools of 
AdoMet for exclusive use for polyamine biosynthesis and has implication for regulation 
of polyamine levels (66, 86). An overview of this process is depicted in Fig. 4. 
 Polyamine metabolism also involves interconversion pathways that can reverse 
the synthesis of the higher order polyamines (87–89). Spermine oxidase (SMO) can 
convert spermine back to spermidine (87). Spermine and spermidine can also be 
acetylated by spermidine/spermine-N1-acetlytransferase (SSAT) (89). The acetylated 
polyamines can be exported out of the cell or serve as substrates to acetylpolyamine 
oxidase (APAO) (89). APAO converts acetylated spermine to spermidine and acetylated 
spermidine to putrescine (66, 90–93). The action of SSAT is important for the regulation 






Figure 4. The Polyamine Synthesis Pathway. Diagram showing the major steps of 
polyamine metabolism. Synthesis begins with an ornithine molecule being converted to 
putrescine via ODC. Spermidine and spermine are synthesized by addition of 
aminopropyl groups. Higher order polyamines can be converted back to lower order 
polyamines via interconversion pathways. Adapted from Pegg 2016 with permission 
(94). 
 
The synthesis of polyamines can be targeted with drugs such as α-
difluoromethylornithine (DFMO) (95). DFMO specifically inhibits ODC, the rate-limiting 
enzyme at the beginning of the polyamine synthesis pathway, by irreversibly binding to 
its active site (95–97). DFMO depletes cellular pools of putrescine and spermidine but is 
not as effective at depleting spermine (98, 99). It has been suggested spermine levels 





DFMO treatment that is converted to spermine. This is evidenced by an increase in the 
activity of AdoMet-DC during DFMO treatment and the observation that cells pulsed 
with radioactive ornithine accumulate radioactive spermine during DFMO treatment (98, 
100). Despite the ubiquitous nature of polyamines and their many roles in cellular 
processes, DFMO is not typically cytotoxic (65, 101–103). However, DFMO has some 
cytostatic effects (65, 95, 99, 102, 104). 
 DFMO is FDA approved is on the WHO list of essential medicines (105). It is 
currently used to treat African trypanosomiasis (106–108) and hirsutism (109). DFMO is 
especially effective against trypanosomes because trypanosomes require spermidine 
for production of the critical antioxidant, trypanothione (110). DFMO is also be 
investigated for its use for treatment or prevention of certain cancers such as colon 
cancer and neuroblastoma (65, 95, 101, 111). DFMO can be taken orally, intravenously, 
or topically (95). Side effects are usually mild and reversible and include gastrointestinal 
upset, anemia, leukopenia, and thrombocytopenia, and reversible hearing loss (102, 
112–114). High doses are often required as DFMO is rapidly eliminated from the blood 
with 80% being excreted in the urine (95, 115). The serum half-life is 1.5-5 hours (115). 
DFMO can be administered 400-800 mg/kg/day intravenously to treat African 
trypanosomiasis (95, 115, 116).  
Polyamines and Viruses 
Viruses utilize polyamines for their replication. Polyamine depleting drugs such 
as DFMO drastically inhibit the replication of diverse families of viruses (78, 117–119). 
In DNA viruses like herpes simplex viruses and poxviruses, polyamines are thought to 





allow for more efficient packaging (120–122). In chikungunya and Zika virus polyamines 
function in transcription and translation of viral proteins (123). In Ebola virus, 
polyamines are critical to produce a viral polymerase component by functioning in the 
hypusination of eIF5A (124). In bunyaviruses (La Crosse and Rift Valley fever virus) as 
well as Zika virus, we have shown that the depletion of polyamines results in the 
accumulation of noninfectious particles that stimulate innate immune responses as well 
as interfere with viral replication (125). Polyamines have broad functions in viral 
infection, many of which are not fully elucidated. 
CVB3 is sensitive to depletion of polyamines via DFMO. We have previously 
reported that passage of CVB3 in polyamine depleted conditions generated mutations in 
the 2A and 3C proteases (126). We reported that DFMO inhibits viral protease activity 
and this inhibition is rescued by the mutations that emerged from the passages (126). 
From the passages another mutation had emerged, Q234R, in the VP3 capsid protein 







Figure 5. Location of the VP3234R Mutation. CVB3 capsid showing the VP3234R 
mutation. The mutated residue is highlighted in yellow and circled in white. The VP3 
protein is colored blue. The image on right is zoomed in on a five-fold axis of symmetry. 
The images were generated using Chimera software with the PDB accession 4GB3 for 
the CVB3 capsid structure. 
 
Bunyaviruses 
Bunyaviruses of the Bunyaviridae family are enveloped negative-sense, single 
stranded RNA viruses. Bunyaviruses include a variety of emerging and highly 
pathogenic viruses that cause significant mortality and remain a significant threat to 
public health. They include viruses such as Rift Valley fever virus (RVFV), La Crosse 
virus (LACV), Sin Nombre virus, and Crimean-Congo hemorrhagic fever virus (127).  
RVFV is a mosquito-borne virus that infects humans and livestock in many 
countries throughout Africa. Infections in humans are typically mild and self-limiting but 
in 1-2% of cases RVFV can cause severe complications like blindness, encephalitis, 
fulminant hepatitis, hemorrhagic syndromes, and renal failure (128–132). Infections in 
cattle are often associated with abortions, gastrointestinal hemorrhage, and diffuse 





infections in livestock with abortion rates that can reach 80-100% (128). In 1977, an 
outbreak infected more than 200,000 people and caused more than $115 million in 
livestock losses (128, 133, 134). Vaccines can be utilized prevent the spread of RVFV. 
The live-attenuated MP-12 vaccine has a conditional license for veterinary use from the 
USDA and is undergoing human clinical trials (135, 136) It was generated from 12 serial 
mutagenic passages that led to attenuating mutations (137). There are 23 mutations in 
the MP-12 genome with 9 amino acid substitutions (138, 139). 
LACV is a mosquito-borne virus that is found mainly in the Midwestern and 
Appalachian regions of the United States (140). It infects around 300,000 people each 
year with most infections being mild or asymptomatic (141). In a small subset of those 
infected, encephalitis can occur causing seizures, disorientation, coma, and/or death 
(141, 142). Encephalitic infections can lead to severe neurological sequelae such as 
recurrent seizures, learning disabilities, and hemiparesis (141, 143).  
Flaviviruses 
Flaviviruses of the Flaviviridae family are enveloped positive-sense, single 
stranded RNA viruses. Flaviviruses are typically arthropod-borne viruses transmitted by 
either ticks or mosquitos and include viruses such as Zika virus, yellow fever virus, tick-
borne encephalitis virus, dengue virus, and Japanese encephalitis virus (144). 
Flaviviruses infect millions of people each year and can cause severe diseases such as 
hemorrhagic fevers and encephalitis (144). The WHO estimates that dengue virus 






Zika virus is an emerging flavivirus transmitted mainly by mosquitos that has 
recently caused outbreaks in Yap, French Polynesia, Brazil, and the Americas (147). In 
Yap, Micronesia, it was estimated 73% of Yap residents over the age of three had been 
infected with Zika virus (148). In Salvador, Brazil, seroprevalence studies showed 63% 
of the population had been infected (149). It is difficult to accurately estimate the true 
burden of Zika in the population due to the lack of suitable diagnostic equipment in 
affected areas (150). Zika infections are usually asymptomatic or cause a mild and flu-
like illness but is some cases can cause severe conditions such as meningitis, 
encephalitis, thrombocytopenia, Guillain-Barré syndrome and multi-organ failure (147, 
151–154). Zika infection can also lead to lead congenital abnormalities by infecting 
developing fetuses. This can lead to conditions such as microcephaly, fetal demise, 
hearing loss, ocular abnormalities, epilepsy, and learning disabilities (147, 155–158). 
Aims and Hypothesis 
 Polyamines are utilized by numerous viruses including CVB3. Many of the roles 
that polyamines play in viral replication remain to be elucidated. The goal of this project 
is to investigate where polyamines function in the replication of CVB3 and to use CVB3 
as a model system for application to diverse viruses. The discovery of conserved 
mechanisms of replication across divergent viruses could have significant implications 
for the development of broad-spectrum antiviral therapies. 
We have shown that CVB3 is sensitive to the depletion of polyamines via DFMO. 
To investigate potential pro-viral mechanisms of polyamines during CVB3 replication we 
performed successive passages of CVB3 in polyamine depleted cells with the objective 





passages arose a mutation in the capsid protein VP3 (Q234R). The site of this mutation, 
residue 234, is a residue that has been implicated in CVB3 receptor binding (56). 
 In my first aim I investigated if the VP3234R capsid mutant confers resistance to 
polyamine depletion via DFMO treatment. The mutation could be an adaptation to cell 
culture and not affect replication in polyamine depleted cells. It is therefore imperative to 
investigate its potential resistance to polyamine depletion. I hypothesized that the 
mutant confers resistance as the mutation was derived from passage in polyamine 
depleted cells. Exploring resistant mutants is valuable because they can provide clues 
as to where polyamines are being utilized in CVB3 replication.  
 In my second aim I hypothesized that polyamines play a role in CVB3 attachment 
to cells. The VP3234R mutation was derived from passage of CVB3 in polyamine 
depleted cells and is in a residue involved in receptor binding. I also investigated the 
ability of the VP3234R mutant to rescue any attachment alterations observed with 
polyamine depletion. 
 In my third aim I explored the conservation of the role of polyamines in 
attachment across divergent viruses. Polyamines are utilized by diverse viruses and it is 
possible they share common mechanisms. Revealing this potential commonality 







MATERIALS AND METHODS 
Cell Culture 
Cells were maintained at 37⁰C in 5% CO2, in Dulbecco’s modified Eagle’s medium 
(DMEM; Life Technologies) with bovine serum and penicillin-streptomycin. Vero cells 
were obtained through BEI Resources, NIAID, NIH (NR-10385) and were supplemented 
with 10% new-born calf serum (NBCS; Thermo-Fischer). 293T cells were kindly 
provided by Dr. Ed Campbell and were supplemented with 10% fetal bovine serum 
(FBS; Thermo-Fischer).   
Infection and Enumeration of Viral Titers  
CVB3 (Nancy strain) (159) was derived from the first passage of virus in Vero cells after 
rescue from infectious clone.  The VP3234R virus was generated via site-directed 
mutagenesis of the wildtype CVB3 plasmid using the primers listed in Table 1 with 
Phusion polymerase (Thermo-Fisher). Rift valley fever virus vaccine strain MP-12, 
provided by Dr. Shinji Makino at UTMB, was propagated in Huh7 cells (160). ZIKV 
(strain MR766, NR-50065) and LACV (NR-540) were obtained from Biodefense and 
Emerging Infections (BEI) Research Resources. LACV was propagated in Huh-7 cells. 
ZIKV was propagated in Vero cells. HRV2 was provided by Dr. William T. Jackson and 
was rescued from infectious clone and propagated in Vero cells. For all infections, 





 maintained at -80⁰C. For infection, virus was diluted in serum-free DMEM for a 
multiplicity of infection (MOI) of 0.1 on Vero cells, unless otherwise indicated. Viral 
inoculum was added to the cells and supernatants were collected at specified 
timepoints. To quantify viral titers via plaque assay, dilutions of cell supernatant were 
prepared in serum-free DMEM and used to inoculate confluent monolayers of Vero cells 
for 10 to 15 min at 37⁰C. Cells were overlain with 0.8% agarose in DMEM containing 2% 
NBCS. CVB3 and HRV2 samples were incubated for 2 days at 37⁰C. Cells were fixed 
with 4% formalin and revealed with crystal violet solution (10% crystal violet; Sigma-
Aldrich). Plaques were enumerated and used to back-calculate the number of plaque 
forming units (PFU) per milliliter of collected volume. 
Drug Treatments 
Difluoromethylornithine (DFMO; TargetMol) was diluted to 100 mM solution in sterile 
PBS. For DFMO treatments, cells were trypsinized (Zymo Research) and reseeded with 
fresh medium supplemented with 2% NBCS. Cells were treated with 500 µM DFMO 
unless otherwise indicated. Cells were incubated with DFMO for 96 hours to allow for 
depletion of polyamines in Vero cells. Exogenous polyamines were prepared in a 1:1:1 
solution (putrescine:spermidine:spermine) and added at a concentration of 5 µM to 
either the cell culture supernatant overnight or to the viral inoculum during the 
experiment as indicated. 
Thin-layer Chromatography for Determination of Polyamines 
Polyamines were separated by thin-layer chromatography as previously described 
(161).   For all samples, cells were treated as described prior to being trypsinized and 





perchloric acid. Samples were then incubated overnight at 4 °C. 200 µL of supernatant 
was combined with 200 µL 5 mg/mL dansyl chloride (Sigma Aldrich) in acetone and 100 
µL saturated sodium bicarbonate. Samples were incubated in the dark overnight at 
room temperature. Excess dansyl chloride was cleared by incubating the reaction with 
100 µL 150 mg/mL proline (Sigma Aldrich). Dansylated polyamines were extracted with 
50 µL toluene (Sigma Aldrich) and centrifuged. Five microliter of sample was added in 
small spots to the TLC plate (silica gel matrix; Sigma Aldrich) and exposed to ascending 
chromatography with 1:1 cyclohexane: ethyl acetate. The plate was dried and visualized 
via exposure to UV. 
RNA Purification and cDNA Synthesis  
Media was cleared from cells and Trizol reagent (Zymo Research) directly added. 
Lysate was then collected, and RNA was purified through phenol chloroform extraction. 
Purified RNA was subsequently used for cDNA synthesis using High Capacity cDNA 
Reverse Transcription Kits (Thermo-Fischer), according to the manufacturer’s protocol, 
with 10-100 ng of RNA and random hexamer primers. 
qPCR-based Attachment Assay 
Vero cells were seeded at 1 x 104 cells per well in 24 well plates in DMEM with 2% 
NBCS. The cells were treated for 96 hours with 500 µM DFMO. After 96 hours, the cells 
were placed on ice and the media was aspirated from the cells and replaced with 200 
uL of serum free media containing virus. The infected cells incubated on ice for a 
specified amount of time. The cells were then washed 3x with PBS and then 250 µL of 
Trizol was added to the cells. The RNA was extracted with a phenol-chloroform 





Green (DotScientific) using a one-step protocol using QuantStudio 3 (ThermoFisher 
Scientific). Relative genomes calculated using the ΔCT method, normalized to β-actin 
qRT-PCR control and calculated as fraction of the unwashed samples. Primer 
sequences are included in Table 1. Primers were verified for linearity using eight-fold 
serial diluted cDNA and checked for specificity via melt curve analysis. 
Single Cycle Replication Attachment Assay 
Vero cells were seeded at 1 x 104 cells per well in 24 well plates in DMEM with 2% 
NBCS. The cells were treated for 96 hours with 500 µM DFMO. After 96 hours, the cells 
were placed on ice and the media was aspirated from the cells and replaced with 200 
uL of serum free media containing virus. The infected cells incubated on ice for a 
specified amount of time. The cells were then washed 3x with PBS. 500 uL of fresh 
DMEM with 2% NBCS were added back to the cells. The infected cells incubated at 
37°C for approximately one replication cycle (≈12-15 hours). The supernatant was 
collected, and virus was quantified via plaque assay as described. 
Plaque Formation Attachment Assay 
Vero cells were seeded in 6 well plates and grown to confluence in DMEM with 2% 
NBCS. The cells were treated for 96 hours with 500 µM DFMO. For polyamine rescue 
experiments, cells were treated overnight before the infection with a 10 µM mix of 
polyamines (putrescine, spermidine, spermine from Millipore Sigma) added directly to 
the media. After the 96 hour DFMO treatment, the cells were placed on ice and the 
media was aspirated from the cells and replaced with 1 mL serum free media containing 
either 1000, 5000, or 10000 PFU. The infected cells incubated on ice for a specified 





overlaid with 0.8% agarose containing DMEM with 2% NBCS. The plates were 
incubated at 37°C for plaques to develop. CVB3 was incubated for 2 days; the VP3234R 
mutant, MP-12, and ZIKV for 3 days; and LACV for 4 days. The cells were fixed with 4% 
formalin, and the plaques were visualized with crystal violet staining. 
Statistical Analysis  
Prism 6 (GraphPad) was used to generate graphs and perform statistical analysis. For 
all analyses, two-tailed Student’s t test was used to compare groups, unless otherwise 
noted, with a = 0.05. For tests of sample proportions, p values were derived from 
calculated Z scores with two tails and a = 0.05. 
Table 1. List of Primers 

























Verification of Polyamine Depletion 
DFMO depletes cellular polyamines by inhibiting the rate-limiting enzyme at the 
beginning of the polyamine biosynthetic pathway (95–97). To verify that DFMO depletes 
cellular polyamine pools we performed thin layer chromatography (TLC) to visualize 
cellular polyamines. Vero cells were treated with increasing doses of DFMO. 
Polyamines were labelled with dansyl groups that were visualized with UV.  
We find that putrescine and spermidine are effectively depleted with DFMO 
treatment while spermine may be slightly reduced (Fig. 6). These results agree with the 
literature that DFMO depletes putrescine and spermidine while not effectively depleting 
spermine (98, 99).
 
Figure 6. DFMO Treatment Depletes Polyamines. Thin layer chromatography 
visualizing putrescine (Put), spermidine (Spd), and spermine (Spm) performed on Vero 





VP3234R Mutant Virus DFMO Resistance Characterization 
We observed a mutation in the capsid protein VP3234R arose from passage of 
CVB3 on DFMO treated Vero cells. To test whether this mutation confers resistance to 
polyamine depletion or if this mutation is simply an adaptation to cell culture, we 
generated VP3234R mutant CVB3 using site-directed mutagenesis. We treated cells with 
increasing doses of DFMO, from 1 µM to 1 mM, and infected with WT or VP3234R mutant 
viruses at a multiplicity of infection (MOI) of 0.1 plaque-forming units (PFU) per cell. At 
48 hours post infection (hpi), we measured virus titers via plaque assay and observed 
significant resistance in the VP3234R mutant, while WT CVB3 exhibited sensitivity to 
DFMO (Fig. 7A). To ensure the resistance observed was not due to kinetic differences 
in the replication of the viruses, we measured viral titers in response to 500 µM DFMO 
treatment over a time course. Vero cells were infected at an MOI of 0.1 and viral titers 
were determined by plaque assay. The VP3234R mutant replicated to a higher titer than 
the WT virus in the DFMO treated cells (Fig. 7B). While the VP3234R mutant and the WT 
virus both reached similar maximum titers throughout the time course, the VP3234R 






Figure 7. VP3234R Mutation Enhances CVB3 Replication in Polyamine-depleted 
Cells. A) Vero cells were either untreated or treated with increasing doses of DFMO (1 
µM, 10 µM, 100 µM, 500 µM, and 1 mM). The cells were infected with the either the WT 
or VP3234R mutant viruses. Supernatant was collected at 24 hours and titered via 
plaque assay. B) Vero cells were either untreated or treated with 500 µM DFMO. The 
cells were infected with the WT and VP3234R mutant viruses. Supernatant was 
collected as specified and titered via plaque assay. *p ≤ 0.05 using Student’s t test (n ≥ 
3), comparing treated samples to untreated controls. Error bars represent ± 1 SEM. 
 
CVB3 Attachment to Polyamine Depleted Cells 
Others have reported that residue 234 in VP3 is important for the binding of 
CVB3 to a receptor (56). Having observed that the Q234R mutation in VP3 confers 
resistance to polyamine depletion via DFMO we hypothesized that the attachment of 
CVB3 to susceptible cells may be altered with DFMO treatment.  
To assess attachment of CVB3 to polyamine-depleted cells, we inoculated 
untreated and DFMO treated cells on ice with the same amount of CVB3. At different 
times the cells were washed with PBS and RNA was collected. Viral genomes were 
reverse-transcribed and quantified by qPCR. Compared to input, cell-associated virus 
genomes were reduced 10,000-fold, which gradually recovered over ten minutes (Fig. 
8A). Interestingly, the polyamine-depleted cells exhibited reduced cell-bound viral 
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genomes compared to the untreated cells at 5 and 10 mins (Fig. 8A). To recapitulate 
the results shown via qPCR we measured attachment of infectious virus. We infected 
untreated and polyamine-depleted cells with CVB3 as before. The cells with the 
inoculum were washed with PBS at different timepoints, and we added back fresh 
media (containing polyamines) to the cells and allowed the bound virus to replicate for 
one replication cycle, ≈12-15 hours. The supernatant from the cells was collected and 
titered via plaque assay. Similar to the qPCR-based attachment assay, DFMO treated 
cells had a marked reduction in viral titers through the 10 min timepoint (Fig. 8B). As an 
additional confirmation of this phenotype, we inoculated untreated and polyamine-
depleted cells as before. Ten minutes later, the cells were washed and overlaid with 
agarose. For two days, bound virus formed plaques in situ. When plaques were 
revealed by crystal violet staining, DFMO treated cells exhibited less bound virus 
compared to the untreated cells (Fig. 8C). Together these results indicate that CVB3 







Figure 8. Polyamine Depletion Precludes CVB3 Binding to Susceptible Cells. A) 
Vero cells untreated or treated with 500 µM DFMO were infected with CVB3 on ice. The 
cells were washed with PBS at different timepoints, RNA was extracted, and bound 
genomes quantified via qPCR, normalizing to cellular β-actin. Cells that were left 
unwashed are abbreviated UW. B) Vero cells untreated or treated with 500 µM DFMO 
were infected with CVB3 on ice. The cells were washed with PBS at different timepoints 
and fresh DMEM with 2% NBCS was replaced on the cells. The infected cells incubated 
at 37°C for approximately one replication cycle before supernatant was collected and 
titered via plaque assay. Cells that were left unwashed are abbreviated UW. C) 
Confluent Vero cells untreated or treated with 500 µM DFMO were infected with 5000 
PFU CVB3 on ice. After 10 minutes, the cells were washed with PBS and overlaid with 
0.8% agarose. Plaques were allowed to form. Shown are representative wells. *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001 using Student’s t test (n ≥ 3), comparing treated samples 
to untreated controls. Error bars represent ± 1 SEM. 
 
Recapitulation of Attachment Phenotype in Alternative Cell Line 
In order to investigate if this reduced attachment phenotype is specific to the 
Vero cell line, we used 293T cells treated with DFMO and performed the qPCR-based 
attachment assay. CVB3 exhibited reduced attachment to 293Ts similarly to Vero cells 
(Fig. 9). This result indicates that the observed phenotype is not Vero cell specific. 





























































Figure 9. Polyamine Depletion Precludes CVB3 Binding to 293T Cells. 293T cells 
were infected with CVB3 on ice. The cells were washed with PBS at different 
timepoints, RNA was extracted, and bound genomes quantified via qPCR, normalizing 
to cellular β-actin. Cells that were left unwashed are abbreviated UW. *p ≤ 0.05, **p ≤ 
0.01 using Student’s t test (n ≥ 3), comparing treated samples to untreated controls. 
Error bars represent ± 1 SEM. 
 
The Ability of the VP3234R Mutant to Recover Attachment Deficits 
We observed that VP3234R confers resistance to DFMO treatment, is in a residue 
involved in CVB3 receptor binding, and CVB3 exhibits diminished binding to DFMO 
treated cells. We next investigated whether this VP3234R mutation could rescue the 
attachment deficiency. We treated Vero cells with DFMO and performed a qPCR 
attachment assay as in Fig. 8A and 9. As before, we observed that WT CVB3 exhibited 
reduced binding to polyamine depleted cells. However, we observed that the VP3234R 
virus binds better than WT in nearly all the timepoints tested in the DFMO treated 
conditions (Fig. 10A). Interestingly, the VP3234R mutant virus bound better to the 
untreated cells in the 0 min timepoint, though both viruses plateaued at similar genome 
levels. We next performed the plaque formation attachment assay to recapitulate these 





























findings. As before (Fig. 8C), WT CVB3 exhibited reduced plaque formation in DFMO-
treated cells (Fig. 10B). However, the VP3234R virus exhibited more plaques in both the 
untreated and the DFMO treated cells compared to the WT virus. These results suggest 
the VP3234R mutant recovers attachment deficits in polyamine depleted treated cells. 
 
Figure 10. VP3234R Mutation Recovers CVB3 Binding to Polyamine-depleted Cells. 
A) Vero cells untreated or treated with 500 µM DFMO were infected with the WT and 
VP3234R viruses on ice. The cells were washed with PBS at different timepoints, RNA 
was extracted, and bound genomes quantified via q CR, normalizing to cellular β-actin. 
B) Confluent Vero cells untreated or treated with 500 µM DFMO were infected with 5000 
PFU WT and VP3234R viruses on ice. The cells were washed with PBS at different 
timepoints and overlaid with 0.8% agarose. Plaques that formed were counted. *p ≤ 
0.05, ***p ≤ 0.001 using Student’s t test (n ≥ 3), comparing treated samples to untreated 
controls. Error bars represent ± 1 SEM. 
 
Investigation into Diverse Viruses 
Polyamine function in the replication of diverse RNA viruses. To investigate the 
conservation of this phenotype with other viruses, we first considered another 
enterovirus, human rhinovirus 2 (HRV2). As with CVB3, we performed the single cycle 
replication attachment assay using Vero cells treated with DFMO. As observed, HRV2 
bound and replicated in untreated cells, with increasing titers observed with increasing 
inoculation time. However, we observed a reduction in viral titers following attachment 
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of the DFMO treated cells to a similar degree compared to CVB3 (Fig. 11A). We next 
explored this phenotype in more diverse viruses. We considered Zika virus (ZIKV), a 
Flavivirus, using the qPCR-based attachment assay. As with the other viruses tested, 
we detect inhibited attachment in the DFMO treated cells (Fig. 11B). Interestingly, the 
attachment reduction with DFMO treatment lasted through 120 mins of incubation. To 
explore more viruses, we performed the plaque formation attachment assay with HRV2, 
ZIKV, and two Bunyaviruses, La Crosse virus (LACV) and the MP-12 strain of Rift 
Valley fever virus. We observed reduced plaque formation in all cases, suggesting that 






Figure 11. Polyamine Depletion Precludes Binding of Diverse Viruses. A) Vero 
cells untreated or treated with 500 µM DFMO were infected with HRV2 on ice. The cells 
were washed with PBS at different timepoints and fresh DMEM with 2% NBCS was 
replaced on the cells. The infected cells incubated at 37°C for approximately one 
replication cycle before supernatant was collected and titered via plaque assay. Cells 
that were left unwashed are abbreviated UW. B) Vero cells untreated or treated with 
500 µM DFMO were infected with ZIKV on ice. The cells were washed with PBS at 
different timepoints, RNA was extracted, and bound genomes quantified via qPCR, 
normalizing to cellular β-actin. Cells that were left unwashed are abbreviated UW. C) 
Confluent Vero cells untreated or treated with 500 µM DFMO were infected with 10000 
PFU HRV2, 5000 PFU ZIKV, 1000 PFU MP-12, and 1000 PFU LACV on ice. The cells 
were washed with PBS after 5 mins and overlaid with 0.8% agarose. Plaques were 
allowed to form. Representative images are shown. *p ≤ 0.05, **p ≤ 0.01 using 
Student’s t test (n ≥ 3), comparing treated samples to untreated controls. Error bars 
represent ± 1 SEM.
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The Ability of Exogenous Polyamines to Rescue Attachment Deficits 
 To investigate if the addition of exogenous polyamines could rescue the 
attachment of virus to polyamine depleted cells, we repeated the plaque formation 
attachment assay with CVB3 and 5 µM polyamines (putrescine, spermine, and 
spermidine) added either to the cell culture supernatant overnight prior to infection or 
directly to the viral inoculum during the experiment. We observed a complete rescue of 
virus attachment between the untreated and the DFMO treated cells with the addition of 
polyamines overnight or to the viral inoculum (Fig. 12A and B). 
 
Figure 12. Attachment Deficits can be Rescued with Exogenous Polyamines. A) 
Confluent Vero cells untreated or treated with 500 µM DFMO were infected with 15000 
PFU CVB3 on ice. A 1:1:1 mix of polyamines was added either to the viral inoculum 
before infection or to the cell supernatant overnight before the infection at a 
concentration of 5 µM. Exogenous polyamines are abbreviated PA. Cells were washed 
with PBS at 5 mins and overlaid with 0.8% agarose. Plaques that formed were counted. 
B) Representative wells from the experiment that is quantified in panel A. ***p ≤ 0.001 
using Student’s t test (n ≥ 3), comparing treated samples to untreated controls. Error 







SUMMARY AND DISCUSSION 
Summary 
Polyamines function in broad areas of virus replication and FDA-approved drugs 
can block diverse virus replication via depletion of polyamines. We investigated novel 
pro-viral roles of polyamines during virus replication by utilizing CVB3 as a model 
system. CVB3 is sensitive to polyamine depletion and is a public health threat due to its 
association with severe brain and heart pathologies. CVB3 was passaged in polyamine 
depleted cells in order to investigate mutations that may allow polyamine independent 
replication. We isolated a mutation in a capsid protein, VP3. 
The mutation in VP3, Q234R, was cloned into CVB3 using site-directed 
mutagenesis. We first investigated the ability of the VP3234R mutant virus to confer 
resistance to polyamine depletion due to the possibility that the mutation could solely be 
an adaptation to cell culture. We find the VP3234R mutant CVB3 is resistant to multiple 
doses of DFMO as well as over a time course of infection. 
The mutated residue in VP3 is involved in CVB3 receptor binding and thus we 
hypothesized that polyamines may be functioning in CVB3 attachment to cells. Through 
a variety of attachment assays we report that CVB3 has inhibited binding to polyamine 
depleted cells. We then show that the VP3234R mutant virus has rescued attachment to 






One of the goals of our study was to employ CVB3 as a model system to find 
broadly conserved functions of polyamines during virus replication. We first investigated 
a related virus, HRV2, for the possible conservation of this polyamine dependent 
attachment phenotype. Through multiple attachment assays we show HRV2 has 
inhibited binding to polyamine depleted cells. To further investigate the extent of this 
phenotype, we performed attachment assays with the flavivirus, Zika, and the 
bunyaviruses, MP-12 and La Crosse. Here we report that polyamines function in the 
attachment of diverse RNA viruses to cells. 
Discussion 
The binding of viruses to susceptible cells is a crucial first step in viral replication 
that has many implications involving tissue tropism, pathogenesis, transmission, and 
restriction of host range (26–34).  Here we describe that diverse viruses exhibited 
binding deficiency to polyamine-depleted cells. Using CVB3 as our model system, we 
observed that polyamine depletion reduces CVB3 binding to susceptible cells and that 
mutation of the capsid protein VP3234R rescues this phenotype. Thus, we have 
uncovered a novel function of polyamines in the replication of RNA viruses. 
The VP3234R Mutant  
The mutation in CVB3 VP3234R that was found to confer DFMO resistance and 
rescue binding, Q234R, is in a residue that has been shown to be important for CVB3 to 
bind to one of its receptors, DAF (56). A potential hypothesis could be that polyamines 
facilitate VP3-DAF interaction; however, our data concerning other, diverse viruses 
suggest that this may not be the case. There is currently no evidence that the other 





mutant rescues CVB3 binding by increasing the attachment to DAF, independent of the 
mechanism that is reducing attachment with DFMO treatment. VP3234R mutant CVB3 
binds to untreated cells better than the WT virus. This hypothetical increase in the 
attachment between CVB3 and DAF would increase CVB3 binding in an environment 
where binding is rendered difficult due to polyamine depletion.  
Potential Mechanisms 
Several mechanisms could be functioning to facilitate virus-cell interactions. First, 
polyamines may enhance virus binding to cells due to their polycationic nature that 
mediates electrostatic interactions between the viral particles and the cell surface. 
Historically, polycationic molecules like DEAE dextran and polybrene enhance binding 
of certain viruses and virus like particles to cells (162–165). It is possible polyamines 
could be playing a similar role. Interestingly, the mutation in VP3, Q234R, generates a 
positive charge at this location. Polyamines are polycationic molecules and possibly the 
loss of the positive charges from polyamines is at least partially restored from the added 
positive charge in VP3, which may substitute for polyamines.  
We have preliminary evidence to support this electrostatic attraction attachment 
hypothesis. Addition of exogenous polyamines directly to the virus inoculum during the 
plaque formation assay appears to fully rescue CVB3 attachment deficits in the DFMO 
treated cells (Fig. S1). The ability of exogenous polyamines to rescue viral attachment 
in such a short timeframe suggests electrostatic mechanisms may be at play. 
An additional factor that may be involved is heparan sulfates. Heparan sulfates 
are a very promiscuous attachment factor that are utilized by many viruses. CVB3 (16, 





Fever virus (25), and many other viruses bind heparan sulfate (15). Heparan sulfates 
are known to be involved in polyamine uptake (166) and cells treated with DFMO have 
increased heparan sulfates with increased affinity for spermine, a biogenic polyamine 
(166). Heparan sulfates are known to be extensively modified during their production 
(167) and the changes that occur in heparan sulfates that increase affinity for spermine 
upon DFMO treatment may coincidentally preclude virus binding to cells. We currently 
have not elucidated the precise mechanism of the effect of polyamines on viral 
attachment, but this is the target of future investigation. An experiment I intend to 
perform to investigate this potential mechanism involves enzymes called heparinases. 
Heparinases can degrade heparan sulfates by breaking glycosidic linkages (168). I plan 
to treat both untreated and DFMO treated cells with heparinases and investigate any 
changes in the attachment phenotype I typically observe with DFMO treatment. If 
heparan sulfates are involved in the polyamine dependent attachment phenotype, I 
expect heparinases to be more effective at reducing attachment to untreated cells than 
DFMO treated cells. I would expect this because the viruses would theoretically have 
impaired binding to DFMO modified heparan sulfate but not to normal heparan sulfate in 
untreated cells. 
Importance 
The FDA approved drug DFMO has been shown to exhibit powerful antiviral 
activity against diverse RNA viruses (117). DFMO inhibits CVB3 replication both in vitro 
and in vivo (117). Our data demonstrate that DFMO inhibits the attachment of not only 
CVB3 but also diverse viruses, and this underscores possible clinical implications of 





pathogenesis, transmission, and the tissue tropism of viruses (26–34); thus if DFMO is 
ever used clinically as an antiviral, it may not only reduce viral titers but may also affect 
the course of disease in patients if the viral attachment alterations have downstream 
effects on the spread of virus between tissues. We also report the emergence of DFMO 
resistant mutant upon passage in DFMO that can rescue viral binding deficits. This 
finding may have implications for DFMO’s clinical use and the importance of 
combination therapies to preclude resistance. Understanding the precise mechanisms 
by which this mutant confers resistance to polyamine depletion is crucial for the 
development and implementation of rational antiviral therapeutics. 
The role in viral attachment is a novel function of polyamines. Polyamine 
involvement in the basic virology of virus-receptor binding, further informs the 
development of antivirals that target host polyamines. Because this phenotype appears 
to be conserved with several other virus families, targeting host cell entry by reducing 
cellular polyamines may limit virus infection. The precise mechanisms by which 
polyamines broadly function to reduce virus-cell attachment remain to be completely 
understood; however, the implications could be broadly applicable to enteroviruses and 






Figure 13. Polyamines are Involved in the Attachment of Viruses. A model 
illustrating the involvement of polyamines in viral attachment. Depletion of polyamines 
via DFMO abrogates viral attachment of CVB3 and other diverse RNA viruses. The 










1.  Strikas RA, Anderson LJ, Parker RA. 1986. Temporal and geographic patterns of 
isolates of nonpolio enterovirus in the United States, 1970-1983. J Infect Dis 
153:346–351. 
2.  Abedi GR. 2018. Enterovirus and Parechovirus Surveillance — United States, 
2014–2016. MMWR Morb Mortal Wkly Rep 67. 
3.  Tao Z, Li B, Xu A, Liu Y, Song L, Wang S, Xiong P, Lin X, Song Y. 2013. 
Seroprevalence of Coxsackievirus B3 in Yantai, China. Jpn J Infect Dis 66:537–
538. 
4.  Martino T A, Liu P, Sole M J. 1994. Viral infection and the pathogenesis of dilated 
cardiomyopathy. Circ Res 74:182–188. 
5.  Tam PE. 2006. Coxsackievirus Myocarditis: Interplay between Virus and Host in 
the Pathogenesis of Heart Disease. Viral Immunol 19:133–146. 
6.  Tao Z, Wang H, Li Y, Liu G, Xu A, Lin X, Song L, Ji F, Wang S, Cui N, Song Y. 
2014. Molecular Epidemiology of Human Enterovirus Associated with Aseptic 
Meningitis in Shandong Province, China, 2006–2012. PLoS ONE 9. 
7.  Hogle JM, Chow M, Filman DJ. 1985. Three-dimensional structure of poliovirus at 
2.9 A resolution. Science 229:1358–1365. 
8.  Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht H-J, 
Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B, Vriend G. 
1985. Structure of a human common cold virus and functional relationship to other 
picornaviruses. Nature 317:145. 
9.  Smyth M, Pettitt T, Symonds A, Martin J. 2003. Identification of the pocket factors 
in a picornavirus. Arch Virol 148:1225–1233. 
10.  Tuthill TJ, Bubeck D, Rowlands DJ, Hogle JM. 2006. Characterization of Early 
Steps in the Poliovirus Infection Process: Receptor-Decorated Liposomes Induce 
Conversion of the Virus to Membrane-Anchored Entry-Intermediate Particles. J 
Virol 80:172–180. 






12.  Oliveira MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, 
Pevear DC, Dutko FJ, McKinlay MA. 1993. The structure of human rhinovirus 16. 
Struct Lond Engl 1993 1:51–68.  
13.  He Y, Chipman PR, Howitt J, Bator CM, Whitt MA, Baker TS, Kuhn RJ, Anderson 
CW, Freimuth P, Rossmann MG. 2001. Interaction of coxsackievirus B3 with the 
full length coxsackievirus-adenovirus receptor. Nat Struct Biol 8:874–878.
14.  Combelas N, Holmblat B, Joffret M-L, Colbère-Garapin F, Delpeyroux F. 2011. 
Recombination between Poliovirus and Coxsackie A Viruses of Species C: A 
Model of Viral Genetic Plasticity and Emergence. Viruses 3:1460–1484. 
15.  Jolly CL, Sattentau QJ. 2013. Attachment Factors, p. 1–23. In Pöhlmann, S, 
Simmons, G (eds.), Viral Entry into Host Cells. Springer New York, New York, NY. 
16.  Wang Y, Pfeiffer JK. 2016. Emergence of a Large-Plaque Variant in Mice Infected 
with Coxsackievirus B3. mBio 7:e00119-16. 
17.  Zautner AE, Körner U, Henke A, Badorff C, Schmidtke M. 2003. Heparan Sulfates 
and Coxsackievirus-Adenovirus Receptor: Each One Mediates Coxsackievirus B3 
PD Infection. J Virol 77:10071–10077. 
18.  Kim SY, Zhao J, Liu X, Fraser K, Lin L, Zhang X, Zhang F, Dordick JS, Linhardt 
RJ. 2017. Interaction of Zika Virus Envelope Protein with Glycosaminoglycans. 
Biochemistry 56:1151–1162. 
19.  Khan AG, Pichler J, Rosemann A, Blaas D. 2007. Human Rhinovirus Type 54 
Infection via Heparan Sulfate Is Less Efficient and Strictly Dependent on Low 
Endosomal pH. J Virol 81:4625–4632. 
20.  Vlasak M, Goesler I, Blaas D. 2005. Human Rhinovirus Type 89 Variants Use 
Heparan Sulfate Proteoglycan for Cell Attachment. J Virol 79:5963–5970. 
21.  Khan AG, Pickl-Herk A, Gajdzik L, Marlovits TC, Fuchs R, Blaas D. 2011. Entry of 
a heparan sulphate-binding HRV8 variant strictly depends on dynamin but not on 
clathrin, caveolin, and flotillin. Virology 412:55–67. 
22.  Tan CW, Poh CL, Sam I-C, Chan YF. 2013. Enterovirus 71 Uses Cell Surface 
Heparan Sulfate Glycosaminoglycan as an Attachment Receptor. J Virol 87:611–
620. 
23.  Zhang X, Shi J, Ye X, Ku Z, Zhang C, Liu Q, Huang Z. 2017. Coxsackievirus A16 
utilizes cell surface heparan sulfate glycosaminoglycans as its attachment 




24.  Goodfellow IG, Sioofy AB, Powell RM, Evans DJ. 2001. Echoviruses Bind 
Heparan Sulfate at the Cell Surface. J Virol 75:4918–4921. 
25.  Riblett AM, Blomen VA, Jae LT, Altamura LA, Doms RW, Brummelkamp TR, 
Wojcechowskyj JA. 2016. A Haploid Genetic Screen Identifies Heparan Sulfate 
Proteoglycans Supporting Rift Valley Fever Virus Infection. J Virol 90:1414–1423. 
26.  Shi Y, Wu Y, Zhang , Qi J, Gao GF. 201 . Enabling the “host jump”  structural 
determinants of receptor-binding specificity in influenza A viruses. Nat Rev 
Microbiol 12:822–831. 
27.  O’Hara SD, Stehle T, Garcea R. 201 . Glycan receptors of the  olyomaviridae  
structure, function, and pathogenesis. Curr Opin Virol 7:73–78. 
28.  van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RAM, Osterhaus 
ADME, Kuiken T. 2006. H5N1 Virus Attachment to Lower Respiratory Tract. 
Science 312:399. 
29.  Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H-D. 2004. Human 
and avian influenza viruses target different cell types in cultures of human airway 
epithelium. Proc Natl Acad Sci U S A 101:4620–4624. 
30.  Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. 
Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. 
Nat Med 15:794–797. 
31.  Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. 2006. Influenza 
virus receptors in the human airway. Nature 440:435. 
32.  Belser JA, Rota PA, Tumpey TM. 2013. Ocular Tropism of Respiratory Viruses. 
Microbiol Mol Biol Rev MMBR 77:144–156. 
33.  de Graaf M, Fouchier RAM. 2014. Role of receptor binding specificity in influenza 
A virus transmission and pathogenesis. EMBO J 33:823–841. 
34.  Dalrymple NA, Mackow ER. 2014. Virus Interactions with Endothelial Cell 
Receptors: Implications for Viral Pathogenesis. Curr Opin Virol 7:134–140. 
35.  Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. 1995. 
Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for 
cell attachment. J Virol 69:3873–3877. 
36.  Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, 
Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a Common Receptor for 




37.  Cohen CJ, Shieh JTC, Pickles RJ, Okegawa T, Hsieh J-T, Bergelson JM. 2001. 
The coxsackievirus and adenovirus receptor is a transmembrane component of 
the tight junction. Proc Natl Acad Sci 98:15191–15196. 
38.  Ortiz-Zapater E, Santis G, Parsons M. 2017. CAR: A key regulator of adhesion 
and inflammation. Int J Biochem Cell Biol 89:1–5. 
39.  Zussy C, Loustalot F, Junyent F, Gardoni F, Bories C, Valero J, Desarménien 
MG, Bernex F, Henaff D, Bayo-Puxan N, Chen J-W, Lonjon N, Koninck Y de, 
Malva JO, Bergelson JM, Luca M di, Schiavo G, Salinas S, Kremer EJ. 2016. 
Coxsackievirus Adenovirus Receptor Loss Impairs Adult Neurogenesis, Synapse 
Content, and Hippocampus Plasticity. J Neurosci 36:9558–9571. 
40.  Tomko RP, Johansson CB, Totrov M, Abagyan R, Frisén J, Philipson L. 2000. 
Expression of the Adenovirus Receptor and Its Interaction with the Fiber Knob. 
Exp Cell Res 255:47–55. 
41.  Kaur T, Mishra B, Saikia UN, Sharma M, Bahl A, Ratho RK. 2012. Expression of 
coxsackievirus and adenovirus receptor and its cellular localization in myocardial 
tissues of dilated cardiomyopathy. Exp Clin Cardiol 17:183–186. 
42.  Matthäus C, Langhorst H, Schütz L, Jüttner R, Rathjen FG. 2017. Cell-cell 
communication mediated by the CAR subgroup of immunoglobulin cell adhesion 
molecules in health and disease. Mol Cell Neurosci 81:32–40. 
43.  Dorner AA, Wegmann F, Butz S, Wolburg-Buchholz K, Wolburg H, Mack A, 
Nasdala I, August B, Westermann J, Rathjen FG, Vestweber D. 2005. 
Coxsackievirus-adenovirus receptor (CAR) is essential for early embryonic 
cardiac development. J Cell Sci 118:3509–3521. 
44.  Mirza M, Pang M-F, Zaini MA, Haiko P, Tammela T, Alitalo K, Philipson L, Fuxe J, 
Sollerbrant K. 2012. Essential Role of the Coxsackie - and Adenovirus Receptor 
(CAR) in Development of the Lymphatic System in Mice. PLoS ONE 7. 
45.  Morton PE, Hicks A, Ortiz-Zapater E, Raghavan S, Pike R, Noble A, Woodfin A, 
Jenkins G, Rayner E, Santis G,  arsons M. 201 . TNFα promotes CAR-
dependent migration of leukocytes across epithelial monolayers. Sci Rep 6:26321. 
46.  Hoffmann EM. 1969. Inhibition of complement by a substance isolated from 
human erythrocytes—II: Studies on the site and mechanism of action. 
Immunochemistry 6:405–419. 
47.  Dho SH, Lim JC, Kim LK. 2018. Beyond the Role of CD55 as a Complement 




48.  Lea S. 2002. Interactions of CD55 with non-complement ligands. Biochem Soc 
Trans 30:1014–1019. 
49.  Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. 1997. Coxsackievirus 
A21 binds to decay-accelerating factor but requires intercellular adhesion 
molecule 1 for cell entry. J Virol 71:4736–4743. 
50.  Bergelson JM, Chan M, Solomon KR, John NFS, Lin H, Finberg RW. 1994. 
Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored 
complement regulatory protein, is a receptor for several echoviruses. Proc Natl 
Acad Sci 91:6245–6248. 
51.  Ward T, Pipkin PA, Clarkson NA, Stone DM, Minor PD, Almond JW. 1994. Decay-
accelerating factor CD55 is identified as the receptor for echovirus 7 using 
CELICS, a rapid immuno-focal cloning method. EMBO J 13:5070–5074. 
52.  Powell RM, Ward T, Goodfellow I, Almond JW, Evans DJ. 1999. Mapping the 
binding domains on decay accelerating factor (DAF) for haemagglutinating 
enteroviruses: implications for the evolution of a DAF-binding phenotype. J Gen 
Virol 80:3145–3152. 
53.  Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K. 1996. 
The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J 
Virol 70:5143–5152. 
54.  Yoder JD, Cifuente JO, Pan J, Bergelson JM, Hafenstein S. 2012. The Crystal 
Structure of a Coxsackievirus B3-RD Variant and a Refined 9-Angstrom Cryo-
Electron Microscopy Reconstruction of the Virus Complexed with Decay-
Accelerating Factor (DAF) Provide a New Footprint of DAF on the Virus Surface. J 
Virol 86:12571–12581. 
55.  Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg 
RW. 1997. Clinical Coxsackievirus B Isolates Differ from Laboratory Strains in 
Their Interaction with Two Cell Surface Receptors. J Infect Dis 175:697–700. 
56.  Pan J, Narayanan B, Shah S, Yoder JD, Cifuente JO, Hafenstein S, Bergelson 
JM. 2011. Single Amino Acid Changes in the Virus Capsid Permit Coxsackievirus 
B3 To Bind Decay-Accelerating Factor. J Virol 85:7436–7443. 
57.  Carson SD, Kim K-S, Pirruccello SJ, Tracy S, Chapman NM. 2007. Endogenous 
low-level expression of the coxsackievirus and adenovirus receptor enables 
coxsackievirus B3 infection of RD cells. J Gen Virol 88:3031–3038. 
58.  Reagan KJ, Goldberg B, Crowell RL. 1984. Altered receptor specificity of 




59.  Bergelson JM, Mohanty JG, Crowell RL, St John NF, Lublin DM, Finberg RW. 
1995. Coxsackievirus B3 adapted to growth in RD cells binds to decay-
accelerating factor (CD55). J Virol 69:1903–1906. 
60.  Coyne CB, Bergelson JM. 2006. Virus-Induced Abl and Fyn Kinase Signals 
Permit Coxsackievirus Entry through Epithelial Tight Junctions. Cell 124:119–131. 
61.  Danthi P, Tosteson M, Li Q, Chow M. 2003. Genome Delivery and Ion Channel 
Properties Are Altered in VP4 Mutants of Poliovirus. J Virol 77:5266–5274. 
62.  Tosteson MT, Chow M. 1997. Characterization of the ion channels formed by 
poliovirus in planar lipid membranes. J Virol 71:507–511. 
63.  Tosteson MT, Wang H, Naumov A, Chow M. 2004. Poliovirus binding to its 
receptor in lipid bilayers results in particle-specific, temperature-sensitive 
channels. J Gen Virol 85:1581–1589. 
64.  Patel KP, Coyne CB, Bergelson JM. 2009. Dynamin- and Lipid Raft-Dependent 
Entry of Decay-Accelerating Factor (DAF)-Binding and Non-DAF-Binding 
Coxsackieviruses into Nonpolarized Cells. J Virol 83:11064–11077. 
65.  Gerner EW, Meyskens FL Jr. 2004. Polyamines and cancer: old molecules, new 
understanding. Nat Rev Cancer 4:781-. 
66.  Pegg AE. 2009. Mammalian polyamine metabolism and function. IUBMB Life 
61:880–894. 
67.  Childs AC, Mehta DJ, Gerner EW. 2003. Polyamine-dependent gene expression. 
Cell Mol Life Sci CMLS 60:1394–1406. 
68.  Igarashi K, Kashiwagi K. 2015. Modulation of protein synthesis by polyamines. 
IUBMB Life 67:160–169. 
69.  Frugier M, Florentz C, Hosseini MW, Lehn JM, Giegé R. 1994. Synthetic 
polyamines stimulate in vitro transcription by T7 RNA polymerase. Nucleic Acids 
Res 22:2784–2790. 
70.  Mandal S, Mandal A, Johansson HE, Orjalo AV, Park MH. 2013. Depletion of 
cellular polyamines, spermidine and spermine, causes a total arrest in translation 
and growth in mammalian cells. Proc Natl Acad Sci 110:2169–2174. 
71.  Fleidervish IA, Libman L, Katz E, Gutnick MJ. 2008. Endogenous polyamines 
regulate cortical neuronal excitability by blocking voltage-gated Na+ channels. 




72.  Nasizadeh S, Myhre L, Thiman L, Alm K, Oredsson S, Persson L. 2005. 
Importance of polyamines in cell cycle kinetics as studied in a transgenic system. 
Exp Cell Res 308:254–264. 
73.  Oredsson SM. 2003. Polyamine dependence of normal cell-cycle progression. 
Biochem Soc Trans 31:366–370. 
74.  Pendeville H, Carpino N, Marine J-C, Takahashi Y, Muller M, Martial JA, 
Cleveland JL. 2001. The Ornithine Decarboxylase Gene Is Essential for Cell 
Survival during Early Murine Development. Mol Cell Biol 21:6549–6558. 
75.  Park MH, Cooper HL, Folk JE. 1981. Identification of hypusine, an unusual amino 
acid, in a protein from human lymphocytes and of spermidine as its biosynthetic 
precursor. Proc Natl Acad Sci 78:2869–2873. 
76.  Park MH, Wolff EC. 2018. Hypusine, a polyamine-derived amino acid critical for 
eukaryotic translation. J Biol Chem jbc.TM118.003341. 
77.  Park MH, Cooper HL, Folk JE. 1982. The biosynthesis of protein-bound hypusine 
(N epsilon -(4-amino-2-hydroxybutyl)lysine). Lysine as the amino acid precursor 
and the intermediate role of deoxyhypusine (N epsilon -(4-aminobutyl)lysine). J 
Biol Chem 257:7217–7222. 
78.  Mounce BC, Olsen ME, Vignuzzi M, Connor JH. 2017. Polyamines and Their Role 
in Virus Infection. Microbiol Mol Biol Rev MMBR 81. 
79.  Hasan R, Alam MK, Ali R. 1995. Polyamine induced Z-conformation of native calf 
thymus DNA. FEBS Lett 368:27–30. 
80.  Feuerstein BG, Pattabiraman N, Marton LJ. 1990. Molecular mechanics of the 
interactions of spermine with DNA: DNA bending as a result of ligand binding. 
Nucleic Acids Res 18:1271–1282. 
81.  Feuerstein BG, Pattabiraman N, Marton LJ. 1989. Molecular dynamics of 
spermine-DNA 1nteractioas sequence specificity and DNA bending for a simple 
ligand. Nucleic Acids Res 17:6883–6892. 
82.  Peng HF, Jackson V. 2000. In Vitro Studies on the Maintenance of Transcription-
induced Stress by Histones and Polyamines. J Biol Chem 275:657–668. 
83.  Naranda T,  učcn Ž. 1 8 . Effect of spermine on the efficiency and fidelity of the 
codon-specific binding of tRNA to the ribosomes. Eur J Biochem 182:291–297. 
84.   ućan Ž, Naranda T,  lohl M, Nöthig-Laslo V, Weygand-Durašević  . 1 88. Effect 




533. In Zappia, V, Pegg, AE (eds.), Progress in Polyamine Research: Novel 
Biochemical, Pharmacological, and Clinical Aspects. Springer US, Boston, MA. 
85.  Pegg AE. 2006. Regulation of Ornithine Decarboxylase. J Biol Chem 281:14529–
14532. 
86.  Ikeguchi Y, Bewley MC, Pegg AE. 2006. Aminopropyltransferases: Function, 
Structure and Genetics. J Biochem (Tokyo) 139:1–9. 
87.  Wang Y, Casero RA. 2006. Mammalian Polyamine Catabolism: A Therapeutic 
Target, a Pathological Problem, or Both? J Biochem (Tokyo) 139:17–25. 
88.  Seiler N. 2004. Catabolism of polyamines. Amino Acids 26:217–233. 
89.  Pegg AE. 2008. Spermidine/spermine-N1-acetyltransferase: a key metabolic 
regulator. Am J Physiol-Endocrinol Metab 294:E995–E1010. 
90.  Wu T, Ling K-Q, Sayre LM, McIntire WS. 2005. Inhibition of murine N1-acetylated 
polyamine oxidase by an acetylenic amine and the allenic amine, MDL 72527. 
Biochem Biophys Res Commun 326:483–490. 
91.  Wang Y, Hacker A, Murray-Stewart T, Frydman B, Valasinas A, Fraser AV, 
Woster PM, Casero RA. 2005. Properties of recombinant human N1-
acetylpolyamine oxidase (hPAO): potential role in determining drug sensitivity. 
Cancer Chemother Pharmacol 56:83–90. 
92.  Takao K, Shibata S, Ozawa T, Wada M, Sugitia Y, Samejima K, Shirahata A. 
2009. A conceptual model of the polyamine binding site of N1-acetylpolyamine 
oxidase developed from a study of polyamine derivatives. Amino Acids 37:401–
405. 
93.  Pozzi MH, Gawandi V, Fitzpatrick PF. 2009. pH Dependence of a Mammalian 
Polyamine Oxidase: Insights into Substrate Specificity and the Role of Lysine 315. 
Biochemistry 48:1508–1516. 
94.  Pegg AE. 2016. Functions of Polyamines in Mammals. J Biol Chem 291:14904–
14912. 
95.  LoGiudice N, Le L, Abuan I, Leizorek Y, Roberts SC. 2018. Alpha-
Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a 
Therapeutic Strategy against Hyperproliferative and Infectious Diseases. Med Sci 
6. 
96.  Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. 1978. Catalytic 
irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by 




97.  Pegg AE, McGovern KA, Wiest L. 1987. Decarboxylation of alpha-
difluoromethylornithine by ornithine decarboxylase. Biochem J 241:305–307. 
98.  Mamont PS, Duchesne M-C, Grove J, Bey P. 1978. Anti-proliferative properties of 
DL-α-difluoromethyl ornithine in cultured cells. A consequence of the irreversible 
inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58–66. 
99.  Wallace HM, Fraser AV. 2004. Inhibitors of polyamine metabolism: Review article. 
Amino Acids 26:353–365. 
100.  Mamont PS, Duchesne M-C, Grove J, Tardif C. 1978. Initial characterization of a 
HTC cell variant partially resistant to the anti-proliferative effect of ornithine 
decarboxylase inhibitors. Exp Cell Res 115:387–393. 
101.  Makena MR, Cho HE, Nguyen TH, Koneru B, Verlekar DU, Hindle A, Kang MH, 
Reynolds CP. 2018. Cytotoxic activity of difluoromethylornithine compared with 
fenretinide in neuroblastoma cell lines. Pediatr Blood Cancer 65:e27447. 
102.  Meyskens FL, Gerner EW. 1999. Development of Difluoromethylornithine (DFMO) 
as a Chemoprevention Agent. Clin Cancer Res 5:945–951. 
103.  Fuller DJM, Gerner EW. 1982. Delayed Sensitization to Heat by Inhibitors of 
Polyamine-biosynthetic Enzymes. Cancer Res 42:5046–5049. 
104.  Ueda A, Araie M, Kubota S. 2008. Polyamine depletion induces G1 and S phase 
arrest in human retinoblastoma Y79 cells. Cancer Cell Int 8:2. 
105.   WHO | WHO Model Lists of Essential Medicines. WHO. 
106.  Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. 1980. Polyamine 
metabolism: a potential therapeutic target in trypanosomes. Science 210:332–
334. 
107.  Milord F, Pépin J, Ethier L, Milord F, Loko L, Ethier L, Mpia B. 1992. Efficacy and 
toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping 
sickness. The Lancet 340:652–655. 
108.  Pepin J, Guern C, Milord F, Schechter PJ. 1987. DIFLUOROMETHYLORNITHINE 
FOR ARSENO-RESISTANT TRYPANOSOMA BRUCEI GAMBIENSE SLEEPING 
SICKNESS. The Lancet 330:1431–1433. 
109.  Wolf JE, Shander D, Huber F, Jackson J, Lin C-S, Mathes BM, Schrode K. 2007. 
Randomized, double-blind clinical evaluation of the efficacy and safety of topical 





110.  Fairlamb AH, Henderson GB, Bacchi CJ, Cerami A. 1987. In vivo effects of 
difluoromethylornithine on trypanothione and polyamine levels in bloodstream 
forms of Trypanosoma brucei. Mol Biochem Parasitol 24:185–191. 
111.  Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens 
FL. 2013. Role of dietary polyamines in a phase III clinical trial of 
difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal 
adenomas. Br J Cancer 108:512–518. 
112.   asic TR, Heisey D,  ove RR. 1  7. α-Difluoromethylornithine Ototoxicity: 
Chemoprevention Clinical Trial Results. Arch Otolaryngol Neck Surg 123:1281–
1286. 
113.  Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, 
Baylin SB. 1984. Phase I trial and pharmacokinetic studies of alpha-
difluoromethylornithine--an inhibitor of polyamine biosynthesis. J Clin Oncol 
2:124–130. 
114.  Meyskens FL, Kingsley EM, Glattke T, Loescher L, Booth A. 1986. A phase II 
study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic 
melanoma. Invest New Drugs 4:257–262. 
115.  Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF, Iriemenam NC. 
2013. A current analysis of chemotherapy strategies for the treatment of human 
African trypanosomiasis. Pathog Glob Health 107:242–252. 
116.  Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, 
Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig 
G, Schmid C, Karunakara U, Torreele E, Kande V. 2009. Nifurtimox-eflornithine 
combination therapy for second-stage African Trypanosoma brucei gambiense 
trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. The 
Lancet 374:56–64. 
117.  Mounce BC, Cesaro T, Moratorio G, Hooikaas PJ, Yakovleva A, Werneke SW, 
Smith EC, Poirier EZ, Simon-Loriere E, Prot M, Tamietti C, Vitry S, Volle R, Khou 
C, Frenkiel M-P, Sakuntabhai A, Delpeyroux F, Pardigon N, Flamand M, Barba-
Spaeth G, Lafon M, Denison MR, Albert ML, Vignuzzi M. 2016. Inhibition of 
Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses. J 
Virol 90:9683–9692. 
118.  Gibson W, Breemen R van, Fields A, LaFemina R, Irmiere A. 1984. D,L-alpha-





119.  Pohjanpelto P, Sekki A, Hukkanen V, von Bonsdorff C-H. 1988. Polyamine 
depletion of cells reduces the infectivity of herpes simplex virus but not the 
infectivity of sindbis virus. Life Sci 42:2011–2018. 
120.  Lanzer W, Holowczak JA. 1975. Polyamines in vaccinia virions and polypeptides 
released from viral cores by acid extraction. J Virol 16:1254–1264. 
121.  Sun S, Rao VB, Rossmann MG. 2010. Genome packaging in viruses. Curr Opin 
Struct Biol 20:114–120. 
122.  Gibson W, Roizman B. 1971. Compartmentalization of Spermine and Spermidine 
in the Herpes Simplex Virion. Proc Natl Acad Sci 68:2818–2821. 
123.  Mounce BC, Poirier EZ, Passoni G, Simon-Loriere E, Cesaro T, Prot M, 
Stapleford KA, Moratorio G, Sakuntabhai A, Levraud J-P, Vignuzzi M. 2016. 
Interferon-Induced Spermidine-Spermine Acetyltransferase and Polyamine 
Depletion Restrict Zika and Chikungunya Viruses. Cell Host Microbe 20:167–177. 
124.  Olsen ME, Filone CM, Rozelle D, Mire CE, Agans KN, Hensley L, Connor JH. 
2016. Polyamines and Hypusination Are Required for Ebolavirus Gene 
Expression and Replication. mBio 7:e00882-16. 
125.  Mastrodomenico V, Esin JJ, Graham ML, Tate PM, Hawkins GM, Sandler ZJ, 
Rademacher DJ, Kicmal TM, Dial CN, Mounce BC. 2019. Polyamine depletion 
inhibits bunyavirus infection via generation of noninfectious interfering virions. J 
Virol JVI.00530-19. 
126.  Dial CN, Tate PM, Kicmal TM, Mounce BC. 2019. Coxsackievirus B3 Responds to 
Polyamine Depletion via Enhancement of 2A and 3C Protease Activity. Viruses 
11:403. 
127.  Guu TSY, Zheng W, Tao YJ. 2012. Bunyavirus: Structure and Replication, p. 
245–266. In Rossmann, MG, Rao, VB (eds.), Viral Molecular Machines. Springer 
US, Boston, MA. 
128.  Bird BH, Ksiazek TG, Nichol ST, MacLachlan NJ. 2009. Rift Valley fever virus. J 
Am Vet Med Assoc 234:883–893. 
129.  Alrajhi AA, Al-Semari A, Al-Watban J. 2004. Rift Valley Fever Encephalitis. Emerg 
Infect Dis 10:554–555. 
130.  McIntosh BM, Russell D, dos Santos I, Gear JH. 1980. Rift Valley fever in humans 
in South Africa. South Afr Med J Suid-Afr Tydskr Vir Geneeskd 58:803–806. 
131.  Al-Hazmi M, Ayoola EA, Abdurahman M, Banzal S, Ashraf J, El-Bushra A, Hazmi 




M, Rahim I, Hafez M, Jambavalikar M, Arishi H, Aqeel A. 2003. Epidemic Rift 
Valley Fever in Saudi Arabia: A Clinical Study of Severe Illness in Humans. Clin 
Infect Dis 36:245–252. 
132.  Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani 
AM, Al-Sayed MO, Abodahish AA, Khan AS, Ksiazek TG, Shobokshi O. 2003. Rift 
Valley Fever Epidemic in Saudi Arabia: Epidemiological, Clinical, and Laboratory 
Characteristics. Clin Infect Dis 37:1084–1092. 
133.  Shimshony A. 1999. Disease prevention and preparedness in cases of animal 
health emergencies in the Middle East. Rev Sci Tech Int Off Epizoot 18:66–75. 
134.  Meegan JM. 1979. The Rift Valley fever epizootic in Egypt 1977–1978 1. 
Description of the epizootic and virological studies. Trans R Soc Trop Med Hyg 
73:618–623. 
135.  Miller MM, Bennett KE, Drolet BS, Lindsay R, Mecham JO, Reeves WK, Weingartl 
HM, Wilson WC. 2015. Evaluation of the Efficacy, Potential for Vector 
Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley 
Fever Virus Vaccine Candidate, in Sheep. Clin Vaccine Immunol 22:930–937. 
136.  Pittman PR, Norris SL, Brown ES, Ranadive MV, Schibly BA, Bettinger GE, 
Lokugamage N, Korman L, Morrill JC, Peters CJ. 2016. Rift Valley Fever MP-12 
Vaccine Phase 2 Clinical Trial: Safety, Immunogenicity, and Genetic 
Characterization of Virus Isolates. Vaccine 34:523–530. 
137.  Caplen H, Peters CJ, Bishop DHL. 1985. Mutagen-directed Attenuation of Rift 
Valley Fever Virus as a Method for Vaccine Development. J Gen Virol 66:2271–
2277. 
138.  Lokugamage N, Freiberg AN, Morrill JC, Ikegami T. 2012. Genetic 
Subpopulations of Rift Valley Fever Virus Strains ZH548 and MP-12 and 
Recombinant MP-12 Strains. J Virol 86:13566–13575. 
139.  Ikegami T, Hill TE, Smith JK, Zhang L, Juelich TL, Gong B, Slack OAL, Ly HJ, 
Lokugamage N, Freiberg AN. 2015. Rift Valley Fever Virus MP-12 Vaccine Is 
Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L 
Segments. J Virol 89:7262–7276. 
140.  Bewick S, Agusto F, Calabrese JM, Muturi EJ, Fagan WF. 2016. Epidemiology of 
La Crosse Virus Emergence, Appalachia Region, United States. Emerg Infect Dis 
22:1921–1929. 
141.  Calisher CH. 1994. Medically important arboviruses of the United States and 




142.  McJunkin JE, de los Reyes EC, Irazuzta JE, Caceres MJ, Khan RR, Minnich LL, 
Fu KD, Lovett GD, Tsai T, Thompson A. 2001. La Crosse Encephalitis in Children. 
N Engl J Med 344:801–807. 
143.  Rust RS, Thompson WH, Matthews CG, Beaty BJ, Chun RWM. 1999. Topical 
Review: La Crosse and Other Forms of California Encephalitis. J Child Neurol 
14:1–14. 
144.  Holbrook MR. 2017. Historical Perspectives on Flavivirus Research. Viruses 9:97. 
145.  Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes 
CL, Farlow AW, Scott TW, Hay SI. 2012. Refining the Global Spatial Limits of 
Dengue Virus Transmission by Evidence-Based Consensus. PLoS Negl Trop Dis 
6. 
146.  Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, 
Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint 
GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution 
and burden of dengue. Nature 496:504–507. 
147.  Pierson TC, Diamond MS. 2018. The emergence of Zika virus and its new clinical 
syndromes. Nature 560:573. 
148.  Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, 
Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert AJ, 
Laven J, Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB. 2009. Zika 
Virus Outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 
360:2536–2543. 
149.  Netto EM, Moreira-Soto A, Pedroso C, Höser C, Funk S, Kucharski AJ, Rockstroh 
A, Kümmerer BM, Sampaio GS, Luz E, Vaz SN, Dias JP, Bastos FA, Cabral R, 
Kistemann T, Ulbert S, Lamballerie X de, Jaenisch T, Brady OJ, Drosten C, Sarno 
M, Brites C, Drexler JF. 2017. High Zika Virus Seroprevalence in Salvador, 
Northeastern Brazil Limits the Potential for Further Outbreaks. mBio 8:e01390-17. 
150.  Musso D, Gubler DJ. 2016. Zika Virus. Clin Microbiol Rev 29:487–524. 
151.  Carteaux G, Maquart M, Bedet A, Contou D, Brugières P, Fourati S, Cleret de 
Langavant L, de Broucker T, Brun-Buisson C, Leparc-Goffart I, Mekontso Dessap 
A. 2016. Zika Virus Associated with Meningoencephalitis. N Engl J Med 
374:1595–1596. 
152.  Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis 
C, Grobusch MP. 2016. Thrombocytopenia and subcutaneous bleedings in a 




153.  Swaminathan S, Schlaberg R, Lewis J, Hanson KE, Couturier MR. 2016. Fatal 
Zika Virus Infection with Secondary Nonsexual Transmission. N Engl J Med 
375:1907–1909. 
154.  Musso D, Bossin H, Mallet HP, Besnard M, Broult J, Baudouin L, Levi JE, Sabino 
EC, Ghawche F, Lanteri MC, Baud D. 2018. Zika virus in French Polynesia 2013–
14: anatomy of a completed outbreak. Lancet Infect Dis 18:e172–e182. 
155.  Ventura CV, Ventura LO. 2018. Ophthalmologic Manifestations Associated With 
Zika Virus Infection. Pediatrics 141:S161–S166. 
156.  Brasil P, Pereira JP, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto 
M, Rabello RS, Valderramos SG, Halai U-A, Salles TS, Zin AA, Horovitz D, Daltro 
P, Boechat M, Raja Gabaglia C, Carvalho de Sequeira P, Pilotto JH, Medialdea-
Carrera R, Cotrim da Cunha D, Abreu de Carvalho LM, Pone M, Machado 
Siqueira A, Calvet GA, Rodrigues Baião AE, Neves ES, Nassar de Carvalho PR, 
Hasue RH, Marschik PB, Einspieler C, Janzen C, Cherry JD, Bispo de Filippis 
AM, Nielsen-Saines K. 2016. Zika Virus Infection in Pregnant Women in Rio de 
Janeiro. N Engl J Med 375:2321–2334. 
157.  Satterfield-Nash A, Kotzky K, Allen J, Bertolli J, Moore CA, Pereira IO, Pessoa A, 
Melo F, Santelli ACF e S, Boyle CA, Peacock G. 2017. Health and Development 
at Age 19–24 Months of 19 Children Who Were Born with Microcephaly and 
Laboratory Evidence of Congenital Zika Virus Infection During the 2015 Zika Virus 
Outbreak — Brazil, 2017. MMWR Morb Mortal Wkly Rep 66:1347–1351. 
158.  Moura da Silva AA, Ganz JSS, Sousa P da S, Doriqui MJR, Ribeiro MRC, Branco 
M dos RFC, Queiroz RC de S, Pacheco M de JT, Vieira da Costa FR, Silva F de 
S, Simões VMF, Pacheco MAB, Lamy-Filho F, Lamy ZC, Soares de Britto e Alves 
MTS. 2016. Early Growth and Neurologic Outcomes of Infants with Probable 
Congenital Zika Virus Syndrome. Emerg Infect Dis 22:1953–1956. 
159.  Kandolf R, Hofschneider PH. 1985. Molecular cloning of the genome of a 
cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant 
cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci 82:4818–
4822. 
160.  Ikegami T, Won S, Peters CJ, Makino S. 2006. Rescue of Infectious Rift Valley 
Fever Virus Entirely from cDNA, Analysis of Virus Lacking the NSs Gene, and 
Expression of a Foreign Gene. J Virol 80:2933–2940. 
161.  Madhubala R. 1998. Thin-layer chromatographic method for assaying polyamines. 




162.  Bailey CA, Miller DK, Lenard J. 1984. Effects of DEAE-dextran on infection and 
hemolysis by VSV. Evidence that nonspecific electrostatic interactions mediate 
effective binding of VSV to cells. Virology 133:111–118. 
163.  Conti C, Mastromarino P, Riccioli A, Orsi N. 1991. Electrostatic interactions in the 
early events of VSV infection. Res Virol 142:17–24. 
164.  Guibinga GH, Miyanohara A, Esko JD, Friedmann T. 2002. Cell Surface Heparan 
Sulfate Is a Receptor for Attachment of Envelope Protein-Free Retrovirus-like 
Particles and VSV-G Pseudotyped MLV-Derived Retrovirus Vectors to Target 
Cells. Mol Ther 5:538–546. 
165.  Nguyen TD, Bottreau E, Aynaud JM. 1987. Transmissible gastroenteritis (TGE) of 
swine: In vitro virus attachment and effects of polyanions and polycations. Vet 
Microbiol 14:343–354. 
166.  Belting M, Persson S, Fransson LA. 1999. Proteoglycan involvement in polyamine 
uptake. Biochem J 338:317–323. 
167.  Sarrazin S, Lamanna WC, Esko JD. 2011. Heparan Sulfate Proteoglycans. Cold 
Spring Harb Perspect Biol 3. 
168.  Galliher PM, Cooney CL, Langer R, Linhardt RJ. 1981. Heparinase production by 








 Thomas Kicmal was born in Park Ridge, Illinois, on May 17, 1994 to Kevin and 
Margaret Kicmal. He earned his Bachelor of Arts degree with a major in Biology with a 
minor in Business Administration from Carthage college in Kenosha, Wisconsin in May 
of 2016. In the summer of 2017, Thomas matriculated to Loyola University Chicago in 
the Infectious Disease and Immunology Master of Science program under the 
mentorship of Dr. Bryan Mounce. 
 Thomas’s work involved exploring drug resistant virus mutants and investigating 
the role of a class of small molecules, polyamines, in the attachment of viruses to cells. 
After completion of his Master of Science degree, Thomas will begin PhD training in the 
Integrated Program in Biomedical Science at Loyola University Chicago.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
